Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 12:25 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1177–1200 of 14,130 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Safety Control Clear all

Conditions: Diabetes Mellitus, Type 2
Interventions: exenatide; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 456 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 60
States / cities: Birmingham, Alabama • Anaheim, California • Bellflower, California + 57 more

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Zidovudine, Sargramostim, Ganciclovir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1992
U.S. locations: 4
States / cities: Los Angeles, California • Boston, Massachusetts • New York, New York + 1 more

Conditions: Rhinitis, Allergic, Perennial
Interventions: Fluticasone furoate nasal spray, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 315 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 12
States / cities: Baltimore, Maryland • Wheaton, Maryland • North Dartmouth, Massachusetts + 9 more

Conditions: Dyslipidemia
Interventions: AZD6615, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 20 Years to 60 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 2
States / cities: Glendale, California • Baltimore, Maryland

Conditions: Epilepsy
Interventions: Brivaracetam, Lorazepam; Drug
Lead sponsor: UCB Biopharma S.P.R.L.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 14
States / cities: Birmingham, Alabama • Tucson, Arizona • Orlando, Florida + 10 more

Conditions: Smoking Cessation Counselling
Interventions: Free Help, Free Nicotine message, Spanish: Free help message, Spanish: Free nicotine message; Behavioral
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 4,171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: San Diego, California

Conditions: Healthy Volunteers, Tauopathies, Alzheimer Disease
Interventions: APNmAb005, Placebo; Drug
Lead sponsor: APRINOIA Therapeutics, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Primary Insomnia
Interventions: Eplivanserin, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 637 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Type2diabetes
Interventions: Prompt-sheet, Usual education; Other
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 45 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Meniere's Disease
Interventions: 200mg SPI-1005 BID, 400mg SPI-1005 BID, Placebo; Drug · Other
Lead sponsor: Sound Pharmaceuticals, Incorporated; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 13
States / cities: Fresno, California • San Diego, California • San Francisco, California + 10 more

Conditions: Acute Liver Failure, Fulminant Hepatic Failure, Primary Graft Non-Function, Surgically-Induced Liver Failure
Interventions: ELAD; Biological
Lead sponsor: Vital Therapies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 18
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Miami, Florida + 14 more

Conditions: Schizophrenia
Interventions: SPD489 low dose range (40mg, 80mg, and 100mg), SPD489 high dose range (120mg, 140mg and 160mg), Placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 4
States / cities: Miami Springs, Florida • O'Fallon, Missouri • Saint Charles, Missouri + 1 more

Conditions: Influenza
Interventions: 2 mg/kg CR8020, 5 mg/kg CR8020, 15 mg/kg CR8020, 30 mg/kg CR8020, 50 mg/kg CR8020, Placebo; Biological
Lead sponsor: Crucell Holland BV; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Diabetic Macular Edema
Interventions: Faricimab, Ranibizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 60
States / cities: Phoenix, Arizona • Tucson, Arizona • Fullerton, California + 53 more

Conditions: Supranuclear Palsy, Progressive
Interventions: BIIB092, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 41 Years to 86 Years
Enrollment: 490 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 33
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 25 more

Conditions: Health Adult Subjects, Obesity & Overweight
Interventions: TIX100, Placebo; Drug
Lead sponsor: TIXiMED, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Post COVID-19 Condition, Long COVID
Interventions: Rintatolimod, Placebo / Normal Saline; Drug · Other
Lead sponsor: AIM ImmunoTech Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 5
States / cities: Canoga Park, California • Inglewood, California • San Diego, California + 2 more

Conditions: Cardiovascular Disease
Interventions: SLCO1B1 Genotype; Genetic
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 40 Years to 75 Years
Enrollment: 408 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Developmental and Epileptic Encephalopathy 1
Interventions: 1.0mg/kg/day PRAX-562, 1.5mg/kg/day PRAX-562, Placebo; Drug
Lead sponsor: Praxis Precision Medicines; Industry
Eligibility: 2 Years to 65 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 6
States / cities: La Jolla, California • Gulf Breeze, Florida • Chevy Chase, Maryland + 3 more

Conditions: Venous Ulcer
Interventions: Autologous Platelet Gel (APG); Procedure
Lead sponsor: National Healing Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 6
States / cities: St. Petersburg, Florida • Titusville, Florida • Newburyport, Massachusetts + 3 more

Conditions: Multiple Sclerosis
Interventions: Fingolimod 1.25 mg, Fingolimod 0.5 mg, Interferon β-1a 30 µg; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,292 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 35
States / cities: Cullman, Alabama • Phoenix, Arizona • Oceanside, California + 31 more

Conditions: Atrial Septal Defect, Ventricular Septal Defect, Atrioventricular Septal Defect
Interventions: Intravenous L-Citrulline, Placebo of Intravenous L-Citrulline; Drug
Lead sponsor: Asklepion Pharmaceuticals, LLC; Industry
Eligibility: Up to 6 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 2
States / cities: St Louis, Missouri • Cincinnati, Ohio

Conditions: Obesity or Overweight, Weight-Related Comorbidity, With/Without Diabetes Mellitus, Type 2
Interventions: Lenbelintide, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 23
States / cities: Escondido, California • Lincoln, California • Walnut Creek, California + 19 more

Conditions: Healthy
Interventions: TG-0054; Drug
Lead sponsor: GPCR Therapeutics, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Study to Examine the Effect on Glucose Control and Safety/Tolerability of Exenatide Given Two Times a Day to Subjects With Type 2 Diabetes

The Safety and Effectiveness of Ganciclovir Used Alone or in Combination With Granulocyte-Macrophage Colony Stimulating Factor in the Treatment of Cytomegalovirus (CMV) of the Eye in Patients With AIDS

A Clinical Study To Test A Nasal Spray (Fluticasone Furoate Nasal Spray) For The Treatment Of Perennial (Year-round) Allergic Rhinitis

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD6615 in Healthy Subjects

A Study to Assess the Efficacy and Safety of Brivaracetam as Treatment for Increased Seizure Activity in an Epilepsy Monitoring Unit Setting

Pragmatic Trial of Text Messages to Recruit Unassisted Tobacco Users Into Quitline Service

A First-in-Human Study to Assess Single Doses of APNmAb005 in Healthy Participants

Efficacy and Safety of Eplivanserin 5mg/Day in Insomnia Characterized by Sleep Maintenance Difficulties

Promoting Alternatives to Sulfonylureas to Improve Patient Safety in Type 2 Diabetes

SPI-1005 for the Treatment of Patients With Meniere's Disease

Safety and Efficacy of the ELAD System (ELAD) to Treat Acute Liver Failure (ALF)

SPD489 Low Dose and High Dose Ranges When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia

Assessment of CR8020, a Monoclonal Antibody Against Influenza A Viruses

A Study of Faricimab (RO6867461) in Participants With Center-Involving Diabetic Macular Edema

Study of BIIB092 in Participants With Progressive Supranuclear Palsy

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Orally Administered TIX100 in Healthy Subjects

Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID Conditions

Integrating Pharmacogenetics In Clinical Care

A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine

Clinical Effectiveness of Topical Autologous Platelet Gel for the Treatment of Venous Ulcers

Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase

Intravenous L-Citrulline to Treat Children Undergoing Heart Bypass Surgery : Revised Protocol

A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus

Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of TG-0054 With Single IV Doses Escalation in Healthy Volunteers